Abstract
Wnt/beta-catenin signaling is constitutively increased in several major classes of tumors arising from the urogenital tract. In this review we focus on this pathway mainly in Wilms tumors and prostate carcinomas, followed by a brief discussion of its potential role in other types of urological tumors. Molecular studies in these types of cancers have highlighted novel components upstream and downstream of this central oncogenic pathway. Beta-catenin gain-of-function mutations are strongly linked to WT1 loss-of-function mutations in syndromic Wilms tumors, and Wnt/beta-catenin signaling increases androgen receptor mRNA expression and blocks apoptosis in prostate cancers. Novel downstream target genes activated by Wnt/beta-catenin signaling are emerging from expression profiling in genetically defined classes of Wilms tumors, and similar analyses are expected to reveal additional downstream genes of this pathway specific to prostate cancers. The identities of these genes will likely suggest new targeted therapies for urological malignancies.
Keywords: Wilms tumor, kidney development, prostate cancer, Wnt, beta-catenin, WT1, androgen receptor, urological tumors
Current Molecular Medicine
Title: The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers
Volume: 7 Issue: 5
Author(s): Benjamin Tycko, Chi-Ming Li and Ralph Buttyan
Affiliation:
Keywords: Wilms tumor, kidney development, prostate cancer, Wnt, beta-catenin, WT1, androgen receptor, urological tumors
Abstract: Wnt/beta-catenin signaling is constitutively increased in several major classes of tumors arising from the urogenital tract. In this review we focus on this pathway mainly in Wilms tumors and prostate carcinomas, followed by a brief discussion of its potential role in other types of urological tumors. Molecular studies in these types of cancers have highlighted novel components upstream and downstream of this central oncogenic pathway. Beta-catenin gain-of-function mutations are strongly linked to WT1 loss-of-function mutations in syndromic Wilms tumors, and Wnt/beta-catenin signaling increases androgen receptor mRNA expression and blocks apoptosis in prostate cancers. Novel downstream target genes activated by Wnt/beta-catenin signaling are emerging from expression profiling in genetically defined classes of Wilms tumors, and similar analyses are expected to reveal additional downstream genes of this pathway specific to prostate cancers. The identities of these genes will likely suggest new targeted therapies for urological malignancies.
Export Options
About this article
Cite this article as:
Benjamin Tycko , Chi-Ming Li and Ralph Buttyan , The Wnt/Beta-Catenin Pathway in Wilms Tumors and Prostate Cancers, Current Molecular Medicine 2007; 7 (5) . https://dx.doi.org/10.2174/156652407781387118
DOI https://dx.doi.org/10.2174/156652407781387118 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanisms and Potential Treatment Targets for Ovarian Cancer by Analyzing Transcriptional Regulatory Network
Letters in Drug Design & Discovery Prostate-specific Antigen Levels in Moroccan Diabetic Males: A Cross-sectional Study
Current Diabetes Reviews The Promising Pharmacological Effects and Therapeutic/Medicinal Applications of Punica Granatum L. (Pomegranate) as a Functional Food in Humans and Animals
Recent Patents on Inflammation & Allergy Drug Discovery New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer
Current Drug Targets Novel Therapeutic Strategies Against Cancer: Marine-derived Drugs May Be the Answer?
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Peptides in Imaging and Therapy: Basic and Clinical Perspectives
Current Medicinal Chemistry Synthesis of Cyclodextrin-based Adsorbents and its Application for Organic Pollutant Removal from Water
Current Organic Chemistry Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) The Potential of Flavonolignans in Prostate Cancer Management
Current Medicinal Chemistry Relationship with Metalloproteinase 13, E-cadherin, Homocysteine and Co Factors Folic Acid and Vitamin B12 in Patients Diagnosed with Prostate Cancer
Current Enzyme Inhibition Patent Selections
Recent Patents on Anti-Cancer Drug Discovery MDMA Administration and Heat Shock Proteins Response: Foreseeing a Molecular Link
Current Pharmaceutical Biotechnology Synthetic and Medicinal Prospective of Structurally Modified Curcumins
Current Topics in Medicinal Chemistry Therapeutic Effects of Curcumin against Bladder Cancer: A Review of Possible Molecular Pathways
Anti-Cancer Agents in Medicinal Chemistry Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer
Current Molecular Pharmacology Liposomes: A Review of Manufacturing Techniques and Targeting Strategies
Current Nanoscience Regulation of Female Fertility and Identification of Future Contraceptive Targets
Current Pharmaceutical Design A Novel Information Theoretic Approach to Gene Selection for Cancer Classification Using Microarray Data
Current Bioinformatics Effect of two Antiandrogens as Protectors of Prostate and Brain in a Huntington`s Animal Model
Anti-Cancer Agents in Medicinal Chemistry Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry